Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration

Description

The goal of this clinical trial is to learn if the areas of stressed cells in the retina correlate to areas of disease identified in standard imaging and whether the images are helpful to identify potential areas of concern before symptoms or disease occurs. The main question it aims to answer is: * to evaluate patterns of increased autofluorescence FPF in the setting of geographic atrophy Participants will undergo FPF imaging using the OcuMet Beacon system.

Conditions

Geographic Atrophy, Age-Related Macular Degeneration

Study Overview

Study Details

Study overview

The goal of this clinical trial is to learn if the areas of stressed cells in the retina correlate to areas of disease identified in standard imaging and whether the images are helpful to identify potential areas of concern before symptoms or disease occurs. The main question it aims to answer is: * to evaluate patterns of increased autofluorescence FPF in the setting of geographic atrophy Participants will undergo FPF imaging using the OcuMet Beacon system.

Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration: New Insights From Multimodal Imaging

Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration

Condition
Geographic Atrophy
Intervention / Treatment

-

Contacts and Locations

Madison

Department of Ophthalmology and Visual Sciences, Madison, Wisconsin, United States, 53705

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 50 years or older and may be either male or female of any race
  • * Established diagnosis of GA due to AMD
  • * GA characteristics: GA area of between 1.25 mm² and 23 mm², with seventy percent of eyes having GA area ranging from 2.5 mm2 to 17.5 mm2. GA may be unifocal or multifocal. GA may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal GA. The presence of concurrent peripapillary atrophy will not exclude subjects from participation
  • * Willing to participate as evidenced by signing the written informed consent
  • * Unable to tolerate ophthalmic imaging
  • * Presence of neovascular AMD on OCT as confirmed by an ophthalmologist
  • * Presence of significant media opacity preventing adequate retinal imaging
  • * Presence of concurrent retinal disease which may confound assessment

Ages Eligible for Study

50 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Wisconsin, Madison,

Mihai Mititelu, MD, MPH, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

2025-04